Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety Evaluation of Xigris Drotrecogin Alfa Activated in Hematopoietic Stem Cell Transplant Patients With Severe Sepsis

NCT00067730 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00067730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00067730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety Evaluation of Xigris Drotrecogin Alfa Activated in Hematopoietic Stem Cell Transplant Patients With Severe Sepsis
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2003
Completion date
October 31, 2003
Enrollment
7 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic neoplasms, hematopoietic stem cell transplantation, infection, sepsis